[go: up one dir, main page]

EP3092250A4 - Polynukleotide zur in-vivo-erzeugung von antikörpern - Google Patents

Polynukleotide zur in-vivo-erzeugung von antikörpern Download PDF

Info

Publication number
EP3092250A4
EP3092250A4 EP15735068.7A EP15735068A EP3092250A4 EP 3092250 A4 EP3092250 A4 EP 3092250A4 EP 15735068 A EP15735068 A EP 15735068A EP 3092250 A4 EP3092250 A4 EP 3092250A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
antibodies
vivo production
vivo
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15735068.7A
Other languages
English (en)
French (fr)
Other versions
EP3092250A1 (de
Inventor
Joseph Beene BOLEN
Axel Bouchon
Giuseppe Ciaramella
Eric Yi-Chun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
Moderna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moderna Therapeutics Inc filed Critical Moderna Therapeutics Inc
Publication of EP3092250A1 publication Critical patent/EP3092250A1/de
Publication of EP3092250A4 publication Critical patent/EP3092250A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15735068.7A 2014-01-08 2015-01-08 Polynukleotide zur in-vivo-erzeugung von antikörpern Withdrawn EP3092250A4 (de)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US201461924804P 2014-01-08 2014-01-08
US201461924846P 2014-01-08 2014-01-08
US201461924805P 2014-01-08 2014-01-08
US201461924819P 2014-01-08 2014-01-08
US201461924775P 2014-01-08 2014-01-08
US201461924763P 2014-01-08 2014-01-08
US201461924850P 2014-01-08 2014-01-08
US201461924812P 2014-01-08 2014-01-08
US201461924767P 2014-01-08 2014-01-08
US201461924827P 2014-01-08 2014-01-08
US201461924754P 2014-01-08 2014-01-08
US201461924795P 2014-01-08 2014-01-08
US201461924820P 2014-01-08 2014-01-08
US201461924817P 2014-01-08 2014-01-08
US201461924791P 2014-01-08 2014-01-08
US201461924779P 2014-01-08 2014-01-08
US201461924841P 2014-01-08 2014-01-08
US201461924810P 2014-01-08 2014-01-08
US201461924773P 2014-01-08 2014-01-08
US201461924783P 2014-01-08 2014-01-08
US201461924811P 2014-01-08 2014-01-08
US201461924787P 2014-01-08 2014-01-08
US201461924768P 2014-01-08 2014-01-08
US201461924776P 2014-01-08 2014-01-08
US201461924802P 2014-01-08 2014-01-08
US201461924834P 2014-01-08 2014-01-08
US201461924807P 2014-01-08 2014-01-08
US201461924799P 2014-01-08 2014-01-08
US201461924781P 2014-01-08 2014-01-08
US201461924770P 2014-01-08 2014-01-08
US201461924774P 2014-01-08 2014-01-08
US201461993715P 2014-05-15 2014-05-15
PCT/US2015/010547 WO2015105926A1 (en) 2014-01-08 2015-01-08 Polynucleotides for the in vivo production of antibodies

Publications (2)

Publication Number Publication Date
EP3092250A1 EP3092250A1 (de) 2016-11-16
EP3092250A4 true EP3092250A4 (de) 2017-05-24

Family

ID=53524318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15735068.7A Withdrawn EP3092250A4 (de) 2014-01-08 2015-01-08 Polynukleotide zur in-vivo-erzeugung von antikörpern

Country Status (2)

Country Link
EP (1) EP3092250A4 (de)
WO (1) WO2015105926A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
EP2971010B1 (de) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (de) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynukleotidmoleküle und verwendungen davon
EP3157573A4 (de) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nukleinsäuremoleküle und verwendungen davon
EP3169335B8 (de) 2014-07-16 2019-10-09 ModernaTX, Inc. Kreisförmige polynukleotide
WO2016014846A1 (en) * 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
ES2810701T5 (es) 2015-10-05 2024-07-11 Modernatx Inc Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
US10532109B2 (en) 2016-05-18 2020-01-14 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-DNA chimeras for treatment of HER overexpressing cancers
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
WO2018021188A1 (ja) * 2016-07-26 2018-02-01 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
MA46761A (fr) * 2016-11-10 2019-09-18 Translate Bio Inc Administration sous-cutanée d'arn messager
US20190351055A1 (en) * 2016-11-16 2019-11-21 University Of Baltimore, Maryland Methods for Treating Bone-Related Disorders
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
US20220081479A1 (en) 2018-12-31 2022-03-17 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
EP3972604B1 (de) 2019-05-23 2025-06-04 Novartis AG Ein bruton-tyrosinkinase-inhibitor zur verwendung bei der behandlung von chronischer spontaner urtikaria
US12383629B2 (en) 2019-07-30 2025-08-12 Arizona Board Of Regents On Behalf Of Arizona State University DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US20230272052A1 (en) * 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
CN115210262B (zh) * 2020-09-29 2023-07-14 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
EP4277929A1 (de) * 2021-01-14 2023-11-22 Translate Bio, Inc. Verfahren und zusammensetzungen zur abgabe von mrna-codierten antikörpern
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
CA3218542A1 (en) * 2021-05-12 2022-11-17 Hua Ying Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
MX2024003807A (es) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos.
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4469091A1 (de) 2022-01-28 2024-12-04 CureVac SE Nukleinsäure-kodierte transkriptionsfaktor-inhibitoren
KR102902533B1 (ko) 2022-02-10 2025-12-22 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
JP2025517508A (ja) 2022-05-25 2025-06-05 キュアバック エスイー 核酸ベースのワクチン
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015105926A1 *
TORBEN GJETTING ET AL: "International Journal of Nanomedicine", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 January 2010 (2010-01-01), pages 371 - 383, XP055609161, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950395/pdf/ijn-5-371.pdf> [retrieved on 20190726] *
XIAOYING CHEN ET AL: "Fusion protein linkers: Property, design and functionality", NIH PUBLIC ACCESS AUTHOR MANUSCRIPT, 1 October 2013 (2013-10-01), pages 1 - 32, XP055341428, DOI: 10.1016/j.addr.2012.09.039 *

Also Published As

Publication number Publication date
EP3092250A1 (de) 2016-11-16
WO2015105926A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EP3092250A4 (de) Polynukleotide zur in-vivo-erzeugung von antikörpern
EP3212231A4 (de) Anti-tim-3*-antikörper
EP3212229A4 (de) Anti-tim-3*-antikörper
EP3240564A4 (de) Verfahren zur herstellung langwirkender ctp-modifizierter polypeptide
EP3192864A4 (de) Verfahren zur herstellung von zerebellarem vorläufergewebe
EP3119806A4 (de) Il-21-antikörper
EP3166931A4 (de) Verbessertes verfahren zur herstellung von exametazim
EP3237195A4 (de) Verfahren zur herstellung von pressware
EP3151857A4 (de) Anti-blys-antikörper
EP3177650A4 (de) Anti-ceramit-antikörper
IL248267A0 (en) A process for preparing converted cycloserines
EP3181709A4 (de) Stahlbandherstellungsvorrichtung
HUP1400114A2 (en) Method for the production of peptides
EP3138903A4 (de) Zellen zur herstellung eines humanen antikörpers
EP3227246B8 (de) Oxy-calcinationsverfahren
SI3160985T1 (sl) Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
EP3233120A4 (de) Il-21-antikörper
EP3182981A4 (de) Verfahren zur herstellung von isomaltooligosacchariden
EP3127943A4 (de) Verfahren zur herstellung von nanopartikeln
EP3107883A4 (de) Verfahren zur herstellung von hydrochlorfluorolefinen
EP3242937A4 (de) Verfahren zur herstellung von abienol
IL247443B (en) Process for the preparation of 5-fluorotryptophol
EP3099655A4 (de) Verfahren zur herstellung von hydrochlorfluorolefinen
EP3125685A4 (de) Herstellung von therapeutischen proteinen
EP3233732B8 (de) Verfahren zur herstellung von mono-wasserstoff-trihalosilanen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170424

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 19/34 20060101ALI20170418BHEP

Ipc: C07K 16/18 20060101AFI20170418BHEP

Ipc: A61K 39/395 20060101ALI20170418BHEP

Ipc: C07K 16/28 20060101ALI20170418BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MODERNATX, INC.

17Q First examination report despatched

Effective date: 20190802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20191017